Inclusion Criteria

INCLUSION CRITERIAL:

- Age > or = 18 years.

- Karnofsky performance score > or = 60.

- Histopathologic confirmation of the diagnosis of a solid tumor malignancy. The brain
metastasis diagnosis per se does not have to be pathologically confirmed if the
clinical and neuro radiographic picture is typical.

- MRI (or CT if the patient cannot undergo MRI) evidence of evaluable disease in the
brain.

- Absolute neutrophil count > or = 1,500/mm³. Platelet count > or = 100,000/mm³.

- Hemoglobin > or = 10 g/dl.

- BUN and serum creatinine both < 1.5 times upper limit of normal.

- Total and direct bilirubin both < 1.5 times upper limit of normal.

- SGOT and SGPT both < or = 3 times upper limit of normal.

- Alkaline phosphatase < or = 2 times upper limit of normal.

- At least two weeks must have elapsed from brain biopsy, craniotomy, or other surgery.

- Life expectancy > or = 8 weeks.

- Patient or their legal guardian or legal next-of-kin must provide written informed
consent prior to patient's registration on study.

- At least four weeks must have elapsed from previous external beam radiation therapy,
or eight weeks from stereotactic radiosurgery.

- Patients treated with radiosurgery should have evidence of progression at a distant
site in the brain, or confirmation of tumor progression by biopsy or PET scan.

EXCLUSION CRITERIA:

- Previous treatment with temozolomide, dacarbazine or vinorelbine.

- Patients who have not recovered from all acute toxicities of prior therapies.

- Patients with evidence of leptomeningeal metastases or primary dural metastases.

- Patients who are poor medical risks because of nonmalignant systemic disease, as well
as those with acute infection requiring treatment with intravenous antibiotics.

- Patients whose psychiatric condition would, in the judgment of the principal
investigator, make it unlikely that they could adhere to the requirements of the
protocol.